{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:30:37Z","timestamp":1787851837984,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1136\/ijgc-2024-005700","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:35:18Z","timestamp":1724906118000},"page":"101874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular biology as a driver in therapeutic choices for ovarian cancer"],"prefix":"10.1016","clinical-trial-number":[{"clinical-trial-number":"nct01376752","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01539785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05633199","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05114421","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martina","family":"Arcieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Andreetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6178-2233","authenticated-orcid":false,"given":"Veronica","family":"Tius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zapelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Titone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-0329","authenticated-orcid":false,"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005700_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib3","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3390\/diagnostics13223484","article-title":"Prognosis following surgery for recurrent ovarian cancer and diagnostic criteria predictive of cytoreduction success: a systematic review and meta-analysis","volume":"13","author":"Gaba","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1136\/ijgc-2024-005700_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence- based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib5","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005700_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib8","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib9","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1245\/s10434-020-09366-w","article-title":"Impact of BRCA1\/2 mutations on the efficacy of secondary cytoreductive surgery","volume":"28","author":"Estati","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ygyno.2019.09.020","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study","volume":"155","author":"Marchetti","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005700_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib13","article-title":"Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial","volume":"1","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2024-005700_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/02656736.2023.2165729","article-title":"Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis","volume":"40","author":"Xia","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"10.1136\/ijgc-2024-005700_bib16","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.3390\/jcm12227012","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): new approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis","volume":"12","author":"Della Corte","year":"2023","journal-title":"J Clin Med"},{"key":"10.1136\/ijgc-2024-005700_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2024-005700_bib18","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/JCO.2023.41.16_suppl.5510","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the CHIPOR randomized phase III trial","volume":"41","author":"Classe","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1204886","article-title":"Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients","volume":"13","author":"Kefleyesus","year":"2023","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT trial)","volume":"31","author":"Vizzielli","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib21","article-title":"Pressurized intraperitoneal aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial","volume":"4","author":"Somashekhar","year":"2019","journal-title":"Pleura Perit"},{"key":"10.1136\/ijgc-2024-005700_bib22","volume":"3","author":"Bakrin","year":"2018","journal-title":"Pleura Perit"},{"key":"10.1136\/ijgc-2024-005700_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107250","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review","volume":"49","author":"Taliento","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12957-023-03230-3","article-title":"Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer","volume":"21","author":"Zou","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","article-title":"Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis","volume":"134","author":"Petrillo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib26","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-015-4523-2","article-title":"Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institution experience","volume":"22","author":"Musella","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib27","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3390\/cancers12082239","article-title":"Cytoreductive surgery for heavily pre-treated, platinum-resistant epithelial ovarian carcinoma: a two-center retrospective experience","volume":"12","author":"Tuninetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005700_bib28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","volume":"32","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005700_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib30","first-page":"6951","article-title":"Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?","volume":"35","author":"Fanfani","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2024-005700_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ygyno.2017.07.008","article-title":"Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study","volume":"147","author":"Falcone","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2022.04.005","article-title":"Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis","volume":"166","author":"Guida","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005700_bib34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005700_bib35","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0167-8140(23)08312-3","article-title":"MO-0049 SBRT in ovary cancer patients progressing within PARP-inhibitor maintenance regimen: Epimetheo study","volume":"182","author":"Macchia","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib36","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","article-title":"Platinum versus platinum- combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data","volume":"24","author":"Raja","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib37","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib38","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005700_bib39","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005700_bib40","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102571","article-title":"Treatments for relapsed, BRCA- wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis","volume":"118","author":"Petrelli","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2024-005700_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","article-title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT- ov38): a phase IIIb trial","volume":"34","author":"Pujade-Lauraine","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2024-005700_bib44","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/cncr.33517","article-title":"Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum- sensitive, recurrent ovarian cancer: A meta-analysis","volume":"127","author":"Lee","year":"2021","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005700_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12916-024-03409-9","article-title":"Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer","volume":"22","author":"Li","year":"2024","journal-title":"BMC Med"},{"key":"10.1136\/ijgc-2024-005700_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonz\u00e1lez-Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005700_bib48","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.2023.41.16_suppl.5550","article-title":"Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1\/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib51","first-page":"304","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1136\/ijgc-2024-005700_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib53","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib54","doi-asserted-by":"crossref","first-page":"S788","DOI":"10.1016\/j.annonc.2022.07.657","article-title":"529MO phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA- mutated platinum-sensitive relapsed ovarian cancer","volume":"33","author":"Banerjee","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib55","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-021-01917-7","article-title":"Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine","volume":"40","author":"Nero","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005700_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1335196","article-title":"How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib58","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1136\/ijgc-2024-005700_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00432-024-05654-0","article-title":"Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment","volume":"150","author":"Hu","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1276085","article-title":"Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005700_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:06:40Z","timestamp":1746500800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":61,"alternative-id":["S1048891X25009934"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005700","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biology as a driver in therapeutic choices for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101874"}}